Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUAK1 | O60285 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 6/20 | 0.41 |
| ▸ | EGFR | P00533 | 5/20 | 0.41 |
| ▸ | CSF1R | P07333 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.40 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 2/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756843 | 0.94 | NUAK1 (0.47) | NUAK1PDGFRBPDGFRACCNA2CDK2 | |
| SCHEMBL13756842 | 0.92 | NUAK1 (0.45) | NUAK1CCNA2CDK2CSF1RJAK2 | |
| SCHEMBL13756768 | 0.91 | NUAK1 (0.44) | NUAK1CCNA2CDK2BRD4EGFR | |
| SCHEMBL13756776 | 0.85 | PDGFRB (0.52) | NUAK1PDGFRBPDGFRACCNA2CDK2 | |
| SCHEMBL1657551 | 0.82 | AURKA (0.59) | NUAK1BRD4JAK2JAK1CDK4 | |
| SCHEMBL13756697 | 0.82 | CSF1R (0.41) | CCNA2CDK2BRD4CSF1RJAK2 | |
| SCHEMBL13756691 | 0.81 | AURKA (0.54) | BRD4JAK2JAK1CDK4AURKA | |
| SCHEMBL13756846 | 0.81 | CDK2 (0.44) | CCNA2CDK2JAK2SRCCDK4 | |
| SCHEMBL13756832 | 0.79 | JAK2 (0.56) | CCNA2CDK2BRD4JAK2JAK1 | |
| SCHEMBL13756766 | 0.78 | NTRK1 (0.49) | CCNA2CDK2JAK2JAK1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | NUAK1 488/4885PDGFRB 433/4885PDGFRA 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.